Share Price and Basic Stock Data
Last Updated: November 7, 2025, 6:11 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Zota Health Care Ltd operates within the pharmaceuticals sector and has reported a market capitalization of ₹4,764 Cr. The company’s current share price stands at ₹1,571. Revenue growth has exhibited volatility over recent quarters. For instance, sales increased from ₹29 Cr in June 2022 to ₹45 Cr in September 2023, reflecting a growth trajectory. However, the company’s fiscal year 2025 projections show revenue rising sharply to ₹292 Cr, with a trailing twelve months (TTM) revenue of ₹340 Cr. This growth trend may be indicative of improving market conditions or successful product launches. Nonetheless, the company has faced challenges, including fluctuating operating margins, which stood at 4% for the current period. The quarterly sales numbers display a consistent upward trend, peaking in June 2025, suggesting potential for future expansion if operational hurdles are addressed.
Profitability and Efficiency Metrics
Zota Health Care’s profitability metrics reveal significant challenges, with a reported net profit of -₹58 Cr for FY 2025. The operating profit margin (OPM) has demonstrated instability, recorded at 4% overall, with some quarters reflecting negative margins. The company reported a loss in operating profit for several quarters, notably in March 2024 and December 2024, indicating operational inefficiencies. The interest coverage ratio (ICR) stood at -0.33x, highlighting difficulties in covering interest expenses, which may raise concerns among investors. Additionally, return on equity (ROE) was reported at 36%, suggesting that the company has historically provided strong returns to shareholders, although the recent net losses may impact future performance. The cash conversion cycle (CCC) of 219 days indicates prolonged liquidity challenges, which could hinder operational efficiency if not managed effectively.
Balance Sheet Strength and Financial Ratios
Zota Health Care’s balance sheet reflects a total borrowing of ₹140 Cr against reserves of ₹195 Cr, indicating a manageable debt situation. The company’s current ratio stands at 1.83, suggesting that it holds sufficient current assets to cover its liabilities, which is favorable compared to typical industry standards. However, the price-to-book value (P/BV) ratio of 10.31x raises concerns about overvaluation compared to peers in the pharmaceuticals sector. The company’s total liabilities have increased to ₹439 Cr, reflecting a growing financial commitment. The operating profit before interest, tax, depreciation, and amortization (PBDIT) margin has deteriorated, recorded at -1.25% for FY 2025. This could indicate potential cash flow issues if operational improvements are not implemented. Furthermore, the return on capital employed (ROCE) of -17% suggests that the company is not generating adequate returns from its capital investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Zota Health Care indicates a significant degree of promoter control, with promoters holding 57.42% of the company as of June 2025. This level of ownership may instill confidence among investors regarding management’s commitment. However, foreign institutional investors (FIIs) have increased their stake from 0.07% in September 2022 to 3.82% in June 2025, reflecting growing interest from external investors. Domestic institutional investors (DIIs) have also shown increased participation, rising to 4.25%. The total number of shareholders has expanded to 10,354, suggesting a growing retail investor base. Conversely, the declining promoter shareholding from 68.12% in September 2022 to 57.42% in June 2025 raises concerns about potential dilution of control and may affect investor sentiment negatively. This duality in the shareholding structure reflects both strong internal confidence and cautious external interest.
Outlook, Risks, and Final Insight
The outlook for Zota Health Care hinges on its ability to stabilize profitability and enhance operational efficiency. The significant increase in revenue projections for FY 2025 to ₹292 Cr could signal potential growth if operational challenges are addressed. However, the risks associated with high debt levels and negative profitability metrics cannot be overlooked. The company’s high P/BV ratio suggests that it may be overvalued relative to its current financial performance, which could deter new investments. Additionally, the prolonged cash conversion cycle indicates liquidity risks that need immediate attention. If the company can successfully navigate these challenges and capitalize on its market position, it may improve its financial health and investor confidence. Conversely, failure to address these issues could lead to further declines in profitability and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Zota Health Care Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.86 | 198.43 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 39 | 35 | 37 | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 |
| Expenses | 28 | 34 | 35 | 36 | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 |
| Operating Profit | 1 | 5 | 0 | 1 | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 |
| OPM % | 5% | 12% | 0% | 3% | 3% | 10% | 7% | -3% | -2% | -1% | -8% | 3% | 4% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 2 | 3 | 3 | 4 | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 |
| Profit before tax | -0 | 2 | -3 | -3 | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 |
| Tax % | 119% | 58% | -4% | -15% | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% |
| Net Profit | -1 | 1 | -3 | -3 | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 |
| EPS in Rs | -0.33 | 0.36 | -1.28 | -1.05 | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 |
Last Updated: August 20, 2025, 1:00 am
Below is a detailed analysis of the quarterly data for Zota Health Care Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 7.00 Cr..
- For Expenses, as of Jun 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 100.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears strong and on an upward trend. It has increased from 3.00% (Mar 2025) to 4.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears strong and on an upward trend. It has increased from -14.00 Cr. (Mar 2025) to -13.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 5.00%. The value appears to be increasing, which may not be favorable. It has increased from -10.00% (Mar 2025) to 5.00%, marking an increase of 15.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -13.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.81. The value appears to be declining and may need further review. It has decreased from -4.50 (Mar 2025) to -4.81, marking a decrease of 0.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:06 am
| Metric | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 340 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 341 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | -1 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 5% | 1% | 11% | 5% | 4% | -2% | -0% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 11 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 50 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -59 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -58 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -20.50 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% |
YoY Net Profit Growth
| Year | 2011-2012 | 2014-2015 | 2019-2020 | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 33.33% | -50.00% | -100.00% | -166.67% | -133.33% | -307.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -83.33% | -50.00% | -66.67% | 33.33% | -173.81% |
Zota Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2011-2012 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | 72% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 55% |
| 3 Years: | 72% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -24% |
| Last Year: | -36% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: October 10, 2025, 3:17 pm
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 |
| Borrowings | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 |
| Other Liabilities | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 |
| Fixed Assets | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 |
| Other Assets | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 |
Below is a detailed analysis of the balance sheet data for Zota Health Care Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2024) to 29.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 195.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2024) to 195.00 Cr., marking an increase of 131.00 Cr..
- For Borrowings, as of Mar 2025, the value is 140.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 95.00 Cr. (Mar 2024) to 140.00 Cr., marking an increase of 45.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 76.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2024) to 76.00 Cr., marking an increase of 33.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 439.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 228.00 Cr. (Mar 2024) to 439.00 Cr., marking an increase of 211.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 185.00 Cr.. The value appears strong and on an upward trend. It has increased from 103.00 Cr. (Mar 2024) to 185.00 Cr., marking an increase of 82.00 Cr..
- For CWIP, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 49.00 Cr..
- For Other Assets, as of Mar 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 116.00 Cr. (Mar 2024) to 193.00 Cr., marking an increase of 77.00 Cr..
- For Total Assets, as of Mar 2025, the value is 439.00 Cr.. The value appears strong and on an upward trend. It has increased from 228.00 Cr. (Mar 2024) to 439.00 Cr., marking an increase of 211.00 Cr..
Notably, the Reserves (195.00 Cr.) exceed the Borrowings (140.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -1.00 | 1.00 | 3.00 | 8.00 | 5.00 | 1.00 | 0.00 | -38.00 | -87.00 | -146.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 281 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 113 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 219 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -20.68 | -5.59 | -2.29 | 3.58 | -0.09 |
| Diluted EPS (Rs.) | -19.06 | -5.47 | -2.29 | 3.58 | -0.09 |
| Cash EPS (Rs.) | -4.73 | 2.22 | 2.46 | 5.00 | 1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Revenue From Operations / Share (Rs.) | 102.31 | 69.83 | 55.63 | 52.14 | 43.48 |
| PBDIT / Share (Rs.) | -1.28 | 3.37 | 3.69 | 6.53 | 0.76 |
| PBIT / Share (Rs.) | -16.36 | -4.40 | -1.06 | 5.07 | -0.52 |
| PBT / Share (Rs.) | -20.13 | -6.25 | -1.86 | 4.94 | -0.14 |
| Net Profit / Share (Rs.) | -19.81 | -5.55 | -2.29 | 3.54 | -0.08 |
| NP After MI And SOA / Share (Rs.) | -19.70 | -5.55 | -2.29 | 3.54 | -0.08 |
| PBDIT Margin (%) | -1.25 | 4.82 | 6.63 | 12.52 | 1.76 |
| PBIT Margin (%) | -15.99 | -6.30 | -1.90 | 9.72 | -1.20 |
| PBT Margin (%) | -19.67 | -8.95 | -3.35 | 9.47 | -0.34 |
| Net Profit Margin (%) | -19.36 | -7.94 | -4.12 | 6.78 | -0.19 |
| NP After MI And SOA Margin (%) | -19.25 | -7.94 | -4.12 | 6.78 | -0.19 |
| Return on Networth / Equity (%) | -25.21 | -15.94 | -7.18 | 9.93 | -0.31 |
| Return on Capital Employeed (%) | -13.84 | -7.35 | -2.26 | 12.36 | -1.90 |
| Return On Assets (%) | -12.84 | -6.28 | -3.65 | 6.40 | -0.24 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.87 | 0.93 | 0.94 | 1.25 | 1.23 |
| Current Ratio (X) | 1.83 | 1.51 | 2.08 | 2.14 | 3.36 |
| Quick Ratio (X) | 0.77 | 0.78 | 1.05 | 1.33 | 1.81 |
| Inventory Turnover Ratio (X) | 0.20 | 0.26 | 0.49 | 0.71 | 0.75 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -18.01 | -65.37 | 28.24 | -1175.68 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 45.05 | 61.02 | 20.00 | 82.97 |
| Earning Retention Ratio (%) | 0.00 | 118.01 | 165.37 | 71.76 | 1275.68 |
| Cash Earning Retention Ratio (%) | 0.00 | 54.95 | 38.98 | 80.00 | 17.03 |
| Interest Coverage Ratio (X) | -0.33 | 1.82 | 3.62 | 51.22 | 17.16 |
| Interest Coverage Ratio (Post Tax) (X) | -4.26 | -2.00 | -1.46 | 28.78 | -10.27 |
| Enterprise Value (Cr.) | 2311.57 | 1240.13 | 707.78 | 746.47 | 338.81 |
| EV / Net Operating Revenue (X) | 7.89 | 6.87 | 5.06 | 5.69 | 3.17 |
| EV / EBITDA (X) | -630.75 | 142.37 | 76.17 | 45.44 | 179.81 |
| MarketCap / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| Retention Ratios (%) | 0.00 | 118.01 | 165.37 | 71.75 | 1275.68 |
| Price / BV (X) | 10.31 | 13.63 | 8.82 | 8.35 | 5.13 |
| Price / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| EarningsYield | -0.02 | -0.01 | -0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Zota Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -20.68. This value is below the healthy minimum of 5. It has decreased from -5.59 (Mar 24) to -20.68, marking a decrease of 15.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is -19.06. This value is below the healthy minimum of 5. It has decreased from -5.47 (Mar 24) to -19.06, marking a decrease of 13.59.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.73. This value is below the healthy minimum of 3. It has decreased from 2.22 (Mar 24) to -4.73, marking a decrease of 6.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.31. It has increased from 69.83 (Mar 24) to 102.31, marking an increase of 32.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.28. This value is below the healthy minimum of 2. It has decreased from 3.37 (Mar 24) to -1.28, marking a decrease of 4.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is -16.36. This value is below the healthy minimum of 0. It has decreased from -4.40 (Mar 24) to -16.36, marking a decrease of 11.96.
- For PBT / Share (Rs.), as of Mar 25, the value is -20.13. This value is below the healthy minimum of 0. It has decreased from -6.25 (Mar 24) to -20.13, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -19.81. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.81, marking a decrease of 14.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -19.70. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.70, marking a decrease of 14.15.
- For PBDIT Margin (%), as of Mar 25, the value is -1.25. This value is below the healthy minimum of 10. It has decreased from 4.82 (Mar 24) to -1.25, marking a decrease of 6.07.
- For PBIT Margin (%), as of Mar 25, the value is -15.99. This value is below the healthy minimum of 10. It has decreased from -6.30 (Mar 24) to -15.99, marking a decrease of 9.69.
- For PBT Margin (%), as of Mar 25, the value is -19.67. This value is below the healthy minimum of 10. It has decreased from -8.95 (Mar 24) to -19.67, marking a decrease of 10.72.
- For Net Profit Margin (%), as of Mar 25, the value is -19.36. This value is below the healthy minimum of 5. It has decreased from -7.94 (Mar 24) to -19.36, marking a decrease of 11.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -19.25. This value is below the healthy minimum of 8. It has decreased from -7.94 (Mar 24) to -19.25, marking a decrease of 11.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is -25.21. This value is below the healthy minimum of 15. It has decreased from -15.94 (Mar 24) to -25.21, marking a decrease of 9.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is -13.84. This value is below the healthy minimum of 10. It has decreased from -7.35 (Mar 24) to -13.84, marking a decrease of 6.49.
- For Return On Assets (%), as of Mar 25, the value is -12.84. This value is below the healthy minimum of 5. It has decreased from -6.28 (Mar 24) to -12.84, marking a decrease of 6.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.02, marking a decrease of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has decreased from 0.93 (Mar 24) to 0.87, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.83, marking an increase of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.77, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 4. It has decreased from 0.26 (Mar 24) to 0.20, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -18.01 (Mar 24) to 0.00, marking an increase of 18.01.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 45.05 (Mar 24) to 0.00, marking a decrease of 45.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 54.95 (Mar 24) to 0.00, marking a decrease of 54.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.33. This value is below the healthy minimum of 3. It has decreased from 1.82 (Mar 24) to -0.33, marking a decrease of 2.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -4.26. This value is below the healthy minimum of 3. It has decreased from -2.00 (Mar 24) to -4.26, marking a decrease of 2.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,311.57. It has increased from 1,240.13 (Mar 24) to 2,311.57, marking an increase of 1,071.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 3. It has increased from 6.87 (Mar 24) to 7.89, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is -630.75. This value is below the healthy minimum of 5. It has decreased from 142.37 (Mar 24) to -630.75, marking a decrease of 773.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Price / BV (X), as of Mar 25, the value is 10.31. This value exceeds the healthy maximum of 3. It has decreased from 13.63 (Mar 24) to 10.31, marking a decrease of 3.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zota Health Care Ltd:
- Net Profit Margin: -19.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -13.84% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -25.21% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -4.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 55.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -19.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Zota House, 2/896, Surat Gujarat 395002 | info@zotahealthcare.com http://www.zotahealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketankumar Chandulal Zota | Non Executive Chairman |
| Mr. Moxesh Ketanbhai Zota | Managing Director |
| Mr. Kamlesh Rajnikant Zota | Whole Time Director |
| Mr. Himanshu Muktilal Zota | Whole Time Director |
| Mr. Viren Manukant Zota | Whole Time Director |
| Mr. Laxmi Kant Sharma | Executive Director |
| Mrs. Jaysheeben Nileshkumar Mehta | Ind. Non-Executive Director |
| Mrs. Bhumi Maulik Doshi | Ind. Non-Executive Director |
| Dr.(Mrs.) Varsaben Gaurang Mehta | Ind. Non-Executive Director |
| CA. Dhaval Chandubhai Patwa | Ind. Non-Executive Director |
| CA. Vitrag Sureshkumar Modi | Ind. Non-Executive Director |
| Dr. Dhiren Prafulbhai Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Zota Health Care Ltd?
Zota Health Care Ltd's intrinsic value (as of 07 November 2025) is 449.59 which is 70.71% lower the current market price of 1,535.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,657 Cr. market cap, FY2025-2026 high/low of 1,628/535, reserves of ₹195 Cr, and liabilities of 439 Cr.
What is the Market Cap of Zota Health Care Ltd?
The Market Cap of Zota Health Care Ltd is 4,657 Cr..
What is the current Stock Price of Zota Health Care Ltd as on 07 November 2025?
The current stock price of Zota Health Care Ltd as on 07 November 2025 is 1,535.
What is the High / Low of Zota Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zota Health Care Ltd stocks is 1,628/535.
What is the Stock P/E of Zota Health Care Ltd?
The Stock P/E of Zota Health Care Ltd is .
What is the Book Value of Zota Health Care Ltd?
The Book Value of Zota Health Care Ltd is 104.
What is the Dividend Yield of Zota Health Care Ltd?
The Dividend Yield of Zota Health Care Ltd is 0.07 %.
What is the ROCE of Zota Health Care Ltd?
The ROCE of Zota Health Care Ltd is 17.0 %.
What is the ROE of Zota Health Care Ltd?
The ROE of Zota Health Care Ltd is 36.0 %.
What is the Face Value of Zota Health Care Ltd?
The Face Value of Zota Health Care Ltd is 10.0.